ASLAN selects PharmaNet/i3 as strategic partner for oncology development
ASLAN Pharmaceuticals has selected PharmaNet/i3, inVentiv Health’s clinical segment, as a strategic partner supporting the development of its oncology portfolio in Asia and conducting phase I and phase II clinical trials for two of ASLAN’s compounds.
Dr. Alan Barge, ASLAN’s chief medical officer, said, “We chose to work with PharmaNet/i3 because of the commitment and passion shown by their team and the creative thinking they brought to our oncology development strategy. ASLAN is keen to build a strong strategic relationship with PharmaNet/i3, a company that shares our focus on quality and efficiency.”
PharmaNet/i3 has been conducting clinical studies for innovative oncology products since 1996 and has on-staff oncologists dedicated to the development of cancer treatments. The company has extensive experience in developing a variety of cytotoxic chemotherapies, monoclonal antibodies, pathway inhibitors and therapeutic vaccines. More than 400 local, regional and global oncology clinical trials have been awarded to PharmaNet/i3 in the past five years, including more than a dozen registration programs, seven of which resulted in NDA/MAA approvals.
“Clinical development of oncology therapeutics requires a special understanding of the mechanism of action and the different approaches to cancer therapies,” said Dalvir Gill, Ph.D., president, phase II-IV development, PharmaNet/i3. “ASLAN has a novel and creative approach to personalized medicine and combination therapy. We will work closely with ASLAN to address the unique methodologies needed to evaluate the efficacy and safety of their innovative products and look forward to a long and productive relationship.”